Skip to main content


Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

Fig. 3

Risk ratios for biologic DMARDs and tofacitinib versus placebo across RCTs in DMARD-IR patients. Studies were predominantly on background methotrexate. BID twice daily, CI confidence interval, DMARD(−IR) disease-modifying antirheumatic drug(−inadequate responder), RCT randomized controlled trial, TNFi tumor necrosis factor inhibitors

Back to article page